Korsana Biosciences, Inc. KRSA
Nov 5, 2026, 12:53 PM EST
- YTD
- +238.13%
- 1 year
- +145.39%
- Market cap
- 1.37B
- EPS (ttm)
- -7.07
- Shares out
- 45.54M
- Forward P/E
- -8.59
- YTD return
- +238.13%
- 1-year return
- +145.39%
- Volume
- 56.47K
- Avg volume
- 79.64K
- Open
- 30.56
- Previous close
- 30.56
- Day's range
- 29.91 – 30.61
- 52-week range
- 7.19 – 59.36
- Beta
- 1.84
- Analysts
- Strong Buy
- Price target
- 44.00 (+46.4%)
- Earnings date
- Nov 11, 2026
1Y +18.11 (+153.09%)
Key statistics
- Enterprise value
- 234.23M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 134.16M
- Total debt
- 1.10M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 31.26
- 200-day average
- 22.17
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 44.00
- Target (high)
- 70.00
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.84695 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -3.45 | -0.41 | +3.04 | +88.12% |
| May 5, 2026 | Mar 31, 2026 | -2.66 | -2.66 | 0.00 | 0.00% |
| Mar 17, 2026 | Dec 31, 2025 | -2.66 | -1.75 | +0.91 | +34.21% |
| Nov 12, 2025 | Sep 30, 2025 | -121.80 | -0.30 | +121.50 | +99.75% |
| Aug 5, 2025 | Jun 30, 2025 | — | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Wedbush | init | — | Outperform |
| Sep 28, 2026 | Guggenheim | init | — | Buy |
| Sep 14, 2026 | Stifel | init | — | Buy |
| Sep 14, 2026 | TD Cowen | init | — | Buy |
| Sep 11, 2026 | UBS | init | — | Buy |
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- korsana.com
News
Korsana Biosciences Q3 EPS $(3.19) Misses $(0.85) Estimate 
Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Korsana Biosciences to Participate in Upcoming Investor Conferences 
Wedbush Initiates Coverage On Korsana Biosciences with Outperform Rating, Announces Price Target of $44 
Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70 - Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43
- UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million 
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? 
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
Your note
Sign in to keep a note on KRSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHICKO RHONDA M. CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 25,018 |
| GRAUL REGINA MARGARET | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 107,523 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 15, 2026 | 910,312 |
| HIGGINS MICHAEL J | Director | Stock Award(Grant) | Mar 24, 2025 | 30,740 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kalehua Capital Management LLC | 0.52% | 235,907 | 7.21M | Jun 29, 2026 |
| FMR, LLC | 0.20% | 92,793 | 2.84M | Jun 29, 2026 |
| Balyasny Asset Management LP | 0.10% | 45,359 | 1.39M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 0.09% | 42,680 | 1.30M | Jun 29, 2026 |
| Braidwell LP | 0.05% | 22,413 | 684.94K | Jun 29, 2026 |
| Citadel Advisors Llc | 0.02% | 8,542 | 261.04K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.07% | 31,141 | 951.67K | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.03% | 15,200 | 464.51K | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.02% | 8,668 | 264.89K | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.02% | 8,186 | 250.16K | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.01% | 4,416 | 134.95K | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.01% | 5,351 | 163.53K | Aug 30, 2026 |